Kezar Life Sciences, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Kezar Life Sciences has filed a definitive proxy statement with the SEC related to its upcoming shareholder meeting.
NASDAQ
Kezar Life Sciences invites stockholders to its 2025 Annual Meeting on June 17, 2025, to vote on director elections, executive compensation, and auditor ratification.
NASDAQ
Kezar Life Sciences is holding its annual meeting on June 18, 2024, and is seeking stockholder votes on director elections, executive compensation, auditor ratification, and a potential reverse stock split.
NASDAQ
DEF 14A: Kezar Life Sciences Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance
Kezar Life Sciences is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing, alongside other routine proposals at the upcoming annual meeting.